Skip to main content

Table 1 Median antifungal consumption in hospital units between 2008 and 2016

From: Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital

Drug\Unit MSC Onco Ped AICU BMT TX NICU P Value*
DDD per 1000 patient-days
 Amphotericin B (lipos + deox) 14.2 190.9   239.4 359.0 79.2   < 0.001
P Value   0.002   0.002 0.002 0.045   
  Amphotericin B liposomal 13.8 190.9   237.5 351.3 78.9   < 0.001
  P Value   0.002   0.002 0.002 0.110   
  Amphotericin B deoxycholate 0.4 0.0   3.2 0.0 7.9   0.012
  P Value   0.904   0.110 0.940 0.135   
 Anidulafugin (2010–2016) 1.4 11.6   20.0 6.2 0.0   0.002
P Value   0.009   0.009 0.995 0.568   
 Caspofungin 7.2 28.1   73.3 46.7 2.0   < 0.001
P Value   0.007   0.002 0.057 0.110   
 Fluconazole (IV + PO) 35.7 257.9   160.7 625.6 159.2   < 0.001
P Value   0.002   0.002 0.002 0.002   
  Fluconazole L IV 25.3 163.3   150.7 382.3 52.6   < 0.001
  P Value   0.002   0.002 0.002 0.002   
  Fluconazole PO 11.4 124.9   14.3 134.2 102.8   < 0.001
  P Value   0.002   0.035 0.002 0.002   
 Itraconazole 0.7 2.7   0.6 0.00 14.7   0.001
P Value   0.625   0.690 0.006 0.324   
 Micafungina (2011–2016) 3.7 41.8   71.7 153.6 21.2   0.001
P Value   0.020   0.077 0.020 0.224   
 Posaconazole (2016) 0.0 44.4   6.9 87.3 0.0  
 Voriconazole (IV + PO) 3.1 82.6   22.2 174.4 7.1   < 0.001
P Value   0.002   0.002 0.002 0.495   
  Voriconazole IV 1.7 44.4   16.0 83.0 3.7   < 0.001
  P Value   0.002   0.002 0.002 0.993   
  Voriconazole PO 1.4 42.4   5.4 80.6 3.4   < 0.001
  P Value   0.002   0.007 0.002 0.324   
DOT per 1000 patient-days
 Amphotericin B (lipos + deox) 3.2 29.8 20.2 38.9 85.2 16.0 2.6 < 0.001
P Value   0.002 0.016 0.002 0.002 0.016 0.943  
  Amphotericin B liposomal 2.5 29.8 19.7 36.0 82.8 10.8 0.5 < 0.001
  P Value   0.002 0.004 0.002 0.002 0.134 0.069  
  Amphotericin B deoxycholate 0.4 0.0 0.0 1.6 0.0 5.2 1.1 < 0.001
  P Value   0.745 0.100 0.045 0.966 0.028 0.434  
 Anidulafugin (2010–2016) 1.3 11.2 0.0 18.4 5.4 0.0 0.0 < 0.001
P Value   0.009 0.377 0.009 0.995 0.568 0.005  
 Caspofungin 7.0 27.0 15.0 65.4 45.9 1.8 0.0 < 0.001
P Value   0.007 0.057 0.002 0.089 0.057 0.001  
 Fluconazole (IV + PO) 42.9 237.0 41.5 147.7 420.1 174.4 1.1 < 0.001
P Value   0.002 0.984 0.002 0.002 0.002 0.002  
  Fluconazole L IV 23.4 102.0 29.8 126.7 259.4 51.1 1.1 < 0.001
  P Value   0.002 0.690 0.002 0.002 0.002 0.002  
  Fluconazole PO 20.1 130.4 13.2 23.6 160.6 119.7 0.0 < 0.001
  P Value   0.002 0.057 0.434 0.002 0.002 0.001  
 Itraconazole 0.8 1.2 1.0 0.8 0.0 11.8 0.0 < 0.001
P Value   0.753 1.000 0.812 0.008 0.324 0.001  
 Micafungina (2011–2016) 3.9 45.3 8.5 73.5 225.5 21.8 0.0 < 0.001
P Value   0.020 0.624 0.077 0.020 0.224 0.024  
 Posaconazole (2016) 0.0 3.1 0.0 0.5 6.2 0.0 0.0
 Voriconazole (IV + PO) 5.4 130.1 35.0 25.4 322.3 10.1 0.00 < 0.001
P Value   0.002 0.002 0.002 0.002 0.559 0.001  
  Voriconazole IV 2.6 57.2 14.0 20.1 142.7 4.7 0.00 < 0.001
  P Value   0.002 0.002 0.002 0.002 0.984 0.001  
  Voriconazole PO 2.2 73.7 17.7 7.1 147.7 5.6 0.00 < 0.001
  P Value   0.002 0.028 0.002 0.002 0.276 0.001  
  1. DDD Defined Daily Dose, DOT Days of Therapy, IV Intravenous, PO Oral, MSW Medical and Surgical Wards, Onco Oncology, Ped Pediatrics, AICU Adult Intensive Care Unit, BTM Bone marrow transplant, SOT Solid organ transplant, NICU Neonatal Intensive Care Unit *P values for Kruskal-Wallis tests to test whether in at least one of the units the consumption was different from the others. Other p-values for post-tests with Steel correction that compare each unit with the Medical and Surgical Wards
\